These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37699231)

  • 1. Guillain-Barre syndrome before and during the COVID-19 pandemic in a referral center of Mexico.
    López-Hernández JC; Vargas-Cañas ES; Estrada SA; Galnares-Olalde J
    Gac Med Mex; 2023; 159(4):315-321. PubMed ID: 37699231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barre syndrome during COVID-19 pandemic: experience from a referral healthcare center in Mexico.
    López-Hernández JC; Pérez-Valdez EY; León-Manríquez E; Bazán-Rodríguez L; Galnares-Olalde JA; Jorge-de Saráchaga A; Briseño-Godínez ME; May-Mas RN; Vargas-Cañas ES
    Rev Neurol; 2021 Nov; 73(9):315-320. PubMed ID: 34676529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study.
    Luijten LWG; Leonhard SE; van der Eijk AA; Doets AY; Appeltshauser L; Arends S; Attarian S; Benedetti L; Briani C; Casasnovas C; Castellani F; Dardiotis E; Echaniz-Laguna A; Garssen MPJ; Harbo T; Huizinga R; Humm AM; Jellema K; van der Kooi AJ; Kuitwaard K; Kuntzer T; Kusunoki S; Lascano AM; Martinez-Hernandez E; Rinaldi S; Samijn JPA; Scheidegger O; Tsouni P; Vicino A; Visser LH; Walgaard C; Wang Y; Wirtz PW; Ripellino P; Jacobs BC;
    Brain; 2021 Dec; 144(11):3392-3404. PubMed ID: 34553216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
    Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
    Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome.
    Keddie S; Pakpoor J; Mousele C; Pipis M; Machado PM; Foster M; Record CJ; Keh RYS; Fehmi J; Paterson RW; Bharambe V; Clayton LM; Allen C; Price O; Wall J; Kiss-Csenki A; Rathnasabapathi DP; Geraldes R; Yermakova T; King-Robson J; Zosmer M; Rajakulendran S; Sumaria S; Farmer SF; Nortley R; Marshall CR; Newman EJ; Nirmalananthan N; Kumar G; Pinto AA; Holt J; Lavin TM; Brennan KM; Zandi MS; Jayaseelan DL; Pritchard J; Hadden RDM; Manji H; Willison HJ; Rinaldi S; Carr AS; Lunn MP
    Brain; 2021 Mar; 144(2):682-693. PubMed ID: 33313649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased Incidence of Guillain-Barré Syndrome during the COVID-19 Pandemic: A Retrospective Population-Based Study.
    Hafsteinsdóttir B; Dalemo E; Elíasdóttir Ó; Ólafsson E; Axelsson M
    Neuroepidemiology; 2023; 57(1):1-6. PubMed ID: 36366822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
    García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guillain-Barre syndrome in Mexico: clinical features and validation of Brighton Collaboration Group criteria.
    López-Hernández JC; Galnares-Olalde JA; Gutiérrez A; Estrada SA; García-Grimshaw M; Vargas-Cañas ES
    Rev Neurol; 2022 Apr; 74(8):258-264. PubMed ID: 35383873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the 'Italian factor'.
    Censi S; Bisaccia G; Gallina S; Tomassini V; Uncini A
    Eur J Neurol; 2024 Feb; 31(2):e16094. PubMed ID: 37823707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Guillain-Barre Syndrome Cases during and Prior to the COVID-19 Pandemic: A Multicentric Study.
    Panicker P; R D; Gafoor AV; R PS; Iype T; Jose J; Stanley A
    J Assoc Physicians India; 2023 Sep; 71(9):69-71. PubMed ID: 38700304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.
    Jeong YD; Park S; Lee S; Jang W; Park J; Lee K; Lee J; Kang J; Udeh R; Rahmati M; Yeo SG; Smith L; Lee H; Yon DK
    Sci Rep; 2024 Oct; 14(1):24561. PubMed ID: 39427003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy.
    Garnero M; Del Sette M; Assini A; Beronio A; Capello E; Cabona C; Reni L; Serrati C; Bandini F; Granata A; Pesce G; Mancardi GL; Uccelli A; Schenone A; Benedetti L
    J Neurol Sci; 2020 Nov; 418():117114. PubMed ID: 32947089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.
    Germano F; Bellucci M; Grisanti S; Beronio A; Grazzini M; Coco E; Tassinari T; Della Cava F; De Michelis C; Baldi O; Sivori G; Murialdo A; Cabona C; Durando P; Uccelli A; Schenone A; Franciotta D; Benedetti L
    J Neurol Sci; 2022 Sep; 440():120330. PubMed ID: 35802961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 and Guillain-Barré syndrome: A single-center prospective case series with a 1-year follow-up.
    Ahmad L; Businaro P; Regalbuto S; Gastaldi M; Zardini E; Panzeri M; Vegezzi E; Fiamingo G; Colombo E; Ravaglia S
    Medicine (Baltimore); 2022 Jul; 101(30):e29704. PubMed ID: 35905215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative frequencies and clinical features of Guillain-Barré Syndrome before and during the COVID-19 pandemic in North China.
    Li Y; Zhao R; Li L; Xue H; Meng H; Li G; Liang F; Zhang H; Ma J; Pang X; Wang J; Chang X; Guo J; Zhang W
    BMC Infect Dis; 2024 May; 24(1):541. PubMed ID: 38816802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré Syndrome in Mexico: An Updated Review Amid the Coronavirus Disease 2019 ERA.
    Galnares-Olalde JA; López-Hernández JC; García-Grimshaw M; Valdés-Ferrer SI; Briseño-Godínez ME; de-Sarachaga AJ; Alegría-Loyola MA; Bazán-Rodriguez A; Martínez-Jiménez E; Vargas-Cañas ES
    Rev Invest Clin; 2022 May; 74(3):121-130. PubMed ID: 35345064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome in patients with SARS-CoV-2 infection. Report of three cases.
    Cea G; Romero C; Aguilar S; Salinas R
    Rev Med Chil; 2021 Dec; 149(12):1812-1816. PubMed ID: 35735350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
    Oo WM; Giri P; de Souza A
    J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.